title: Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma.
abstract: We report a case of malignant pheochromocytoma recurred after debulking surgery. A 17-year-old male patient visited our hospital for right flank pain. He had not experienced palpitations, headache, sweating or weight loss. Level of urinary catecholamine and its metabolite increased above normal values and abdominal computed tomography showed a huge right adrenal mass. One month after debulking surgery, anterior mediastinal and multiple liver metastases were found. These tumors had no response to two conventional regimens of combination chemotherapy (cyclophosphamide, vincristine, dacarbazine and anthracycline; and etoposide and cisplatin). We treated the patient with sunitinib, a multiple tyrosine kinase inhibitor. The tumor showed very good metabolic response to the therapy. In patient with malignant pheochromocytoma, sunitinib might be one therapeutic strategy for malignant pheochromocytomas.
authors.affiliation: Department of Oncology and Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Songpa-Gu, Seoul, Republic of Korea.
authors.forename: Kyung-Sun
authors.initials: KS
authors.lastname: Park
authors.forename: Jae-Lyun
authors.initials: JL
authors.lastname: Lee
authors.forename: Hanjong
authors.initials: H
authors.lastname: Ahn
authors.forename: Jung-Min
authors.initials: JM
authors.lastname: Koh
authors.forename: Inkeun
authors.initials: I
authors.lastname: Park
authors.forename: Jun-Seok
authors.initials: JS
authors.lastname: Choi
authors.forename: Yi Rang
authors.initials: YR
authors.lastname: Kim
authors.forename: Tai Sun
authors.initials: TS
authors.lastname: Park
authors.forename: Jin-Hee
authors.initials: JH
authors.lastname: Ahn
authors.forename: Dae Ho
authors.initials: DH
authors.lastname: Lee
authors.forename: Tae Won
authors.initials: TW
authors.lastname: Kim
authors.forename: Jung Shin
authors.initials: JS
authors.lastname: Lee
mesh_terms: D000293:Adolescent; D000310:Adrenal Gland Neoplasms / Q000188:drug therapy* / Q000601:surgery; D018943:Anthracyclines / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008479:Mediastinal Neoplasms / Q000556:secondary; D010673:Pheochromocytoma / Q000188:drug therapy* / Q000601:surgery; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D002945:Cisplatin; D000077210:Sunitinib